UB Paderborn / Katalog / Suche / in CDI

Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization

Antimicrobial Agents and Chemotherapy, 2012-08, Vol.56 (8), p.4365-4374

2012

Volltextzugriff (PDF)

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Journal of Virology, 2007-03, Vol.81 (5), p.2359-2371

2007

Volltextzugriff (PDF)

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Antimicrobial Agents and Chemotherapy, 2005-11, Vol.49 (11), p.4721-4732

2005

Volltextzugriff (PDF)

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Journal of Virology, 2006-05, Vol.80 (10), p.4909-4920

2006

Volltextzugriff (PDF)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

PloS one, 2018-12, Vol.13 (12), p.e0204099

2018

Volltextzugriff (PDF)

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action

Journal of Virology, 2011-07, Vol.85 (13), p.6353-6368

2011

Volltextzugriff (PDF)

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism

Journal of Virology, 2011-05, Vol.85 (9), p.4330-4342

2011

Volltextzugriff (PDF)

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4451-4463

2010

Volltextzugriff (PDF)

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2012-03, Vol.56 (3), p.1331-1341

2012

Volltextzugriff (PDF)

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Cancer cell international, 2019-12, Vol.19 (1), p.346-346, Article 346

2019

Volltextzugriff (PDF)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

Retrovirology, 2011-11, Vol.8 (1), p.89-89, Article 89

2011

Volltextzugriff (PDF)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Retrovirology, 2013-04, Vol.10 (1), p.43-43, Article 43

2013

Volltextzugriff (PDF)

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

Antiviral Chemistry and Chemotherapy, 2005-12, Vol.16 (6), p.339-354

2005

Volltextzugriff (PDF)

Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 Cells

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4311-4319

2011

Volltextzugriff (PDF)

CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on

Antiviral Chemistry and Chemotherapy, 2010-06, Vol.20 (5), p.179-192

2010

Volltextzugriff (PDF)

Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease

Virology journal, 2010-09, Vol.7 (1), p.250-250, Article 250

2010

Volltextzugriff (PDF)

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

2008

Volltextzugriff (PDF)

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

The Journal of infectious diseases, 2010-03, Vol.201 (6), p.803-813

2010

Volltextzugriff (PDF)

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1

The Journal of infectious diseases, 2009-06, Vol.199 (11), p.1638-1647

2009

Volltextzugriff (PDF)

Inhibitors of viral entry

Handbook of experimental pharmacology, 2009 (189), p.177

2009

Volltextzugriff (PDF)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor

Journal of virology, 2015-11, Vol.89 (22), p.11457-11472

2015

Volltextzugriff (PDF)

Abstract 4862: AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of distal lesions and is synergistic with an anti-PD-1 antibody in a mouse melanoma model

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4862-4862

2016

Volltextzugriff (PDF)

Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer

Journal of molecular medicine (Berlin, Germany), 2015-06, Vol.93 (6), p.619-631

2015

Volltextzugriff (PDF)

Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications

Methods in Enzymology, 2009, Vol.460, p.17-55

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 Cells

An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of N-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)

CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on

Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1

Inhibitors of viral entry

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor

Abstract 4862: AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of distal lesions and is synergistic with an anti-PD-1 antibody in a mouse melanoma model

Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer

Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications

Suchergebnisse filtern